LGM PHARMA
GenericsLGM PHARMA is a generic drug manufacturer focused on Cardiovascular, Metabolic, Immunology.
LGM PHARMA's Key Drugs
LGM PHARMA's core commercial portfolio centers on HYDROCODONE BITARTRATE AND ASPIRIN, spanning Cardiovascular and Metabolic — its most strategically important drugs approved in the last 15 years.
LGM PHARMA's Recent FDA Approvals
New NDA/BLA approvals for LGM PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
LGM PHARMA's Therapeutic Areas
LGM PHARMA's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Metabolic, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LGM PHARMA's Top Competitors
LGM PHARMA's closest competitors by therapeutic-area and drug-target overlap include Sanofi, AstraZeneca, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LGM PHARMA Pipeline Snapshot
Active clinical trials for LGM PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • HYDROCODONE BITARTRATE AND ASPIRIN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2001-11-30
- Latest
- 2026-06-18
- Applications
- 12